๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 454 Fuzhou 9 Hangzhou 8 Zhengzhou 7 Yangzhou 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai454 Fuzhou9 Hangzhou8 Zhengzhou7 Yangzhou5
All 52 locations
Target enrolment
to

Trials in this register

472 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of โ‰ค 2 cm
NCT06634979Lung Cancer (NSCLC), Lymph Node Dissection
Fudan University
Not applicable
684
Shanghai
2024-05-01
Recruiting
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT065616203-year Disease-free Survival
Fudan University
Phase 4
592
Shanghai
2024-05-01
Not yet open
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
NCT06423937Colorectal Cancer
Fudan University
Phase 2
129
Shanghai
2024-05
Not yet open
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06370754Pancreatic Cancer
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
NCT06258642Small Cell Lung Cancer Recurrent
Fudan University
Not applicable
39
Shanghai
2024-04-17
Recruiting
Lymph Node Pathologic Grading Strategy
NCT06745830Lung Adenocarcinoma
Fudan University
Observational
2,998
Shanghai
2024-04-10
Recruiting
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
NCT06402708Thymic Carcinoma
Fudan University
Phase 3
172
Shanghai
2024-04-09
Recruiting
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
NCT06341621Breast Cancer
Fudan University
Phase 3
1,900
Shanghai
2024-04-02
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
NCT06249321Pancreatic Cancer, Radiotherapy
Fudan University
Phase 2
30
Shanghai
2024-04-01
Not yet open
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
NCT06301386Colon Cancer
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer๏ผšChase
NCT07555678Anal Squamous Cell Cancer
Fudan University
Phase 2
241
Shanghai
2024-04-01
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710Lung Cancer Metastatic, Surgical Resection
Fudan University
Observational
66
Shanghai
2024-04-01
Recruiting
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT06525428Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
96
Shanghai
2024-04-01
Recruiting
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
NCT05976152Stroke, Post-stroke Cognitive Impairment (PSCI)
Fudan University
Phase 3
3,200
Dandong
2024-04
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
NCT07400354Gastric Cancer, Gut Microbiota
Fudan University
Observational
300
Shanghai
2024-03-14
Recruiting
Metronomic Capecitabine in Stage III Gastric Cancer
NCT06313567Gastric Cancer
Fudan University
Phase 3
722
Shanghai
2024-03-10
Recruiting
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
NCT06314334Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Recruiting
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
NCT06196788Pancreatic Cancer
Fudan University
Phase 2
30
Shanghai
2024-03-01
Recruiting
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1๏ผŒChemotherapy and Target Therapy for Metastatic Colorectal Cancer
NCT06841159Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
116
Shanghai
2024-03-01
Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963MALT Lymphoma of Stomach, Helicobacter Pylori Infection
Fudan University
Phase 2
160
Shanghai
2024-03
Recruiting
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
NCT07236203Large B-Cell Lymphoma
Fudan University
Observational
80
Shanghai
2024-02-29
Not yet open
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
NCT06217042Pancreatic Cancer
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
NCT06447623Advanced Breast Cancer, HR+/HER2- Breast Cancer
Fudan University
Phase 3
184
Shanghai
2024-02-01
Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
NCT06911528Breast Cancer, Sentinel Lymph Node, Frozen Section, Cytology
Fudan University
Not applicable
709
Shanghai
2024-01-30
Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
Fudan University
Phase 2
66
Shanghai
2024-01-16
Recruiting
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
NCT06243003SCLC,Extensive Stage, Brain Metastases
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
NCT06149689Pancreatic Adenocarcinoma
Fudan University
Phase 2
30
Shanghai
2024-01-10
Recruiting
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
NCT06230055HER2-negative Breast Cancer, Leptomeningeal Metastasis
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
NCT06202404Metastasis, Predictive Cancer Model
Fudan University
Observational
166
Shanghai
2024-01-01
Recruiting
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
NCT07561060Rectal Cancer
Fudan University
Phase 1/2
50
Shanghai
2024-01-01
Recruiting
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
NCT06218810Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
Fudan University
Phase 2
53
Shanghai
2024-01-01
Not yet open
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
NCT06156267Pancreatic Cancer
Fudan University
Phase EARLY_PHASE1
30
Shanghai
2024-01
Recruiting
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
NCT06440902Colorectal Cancer Metastatic
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
Active, closed
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
NCT06401447Esophageal Squamous Cell Carcinoma
Fudan University
Not applicable
50
Shanghai
2023-12-21
Recruiting
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147Pancreatic Cancer
Fudan University
Observational
276
Shanghai
2023-12-18
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308Ovarian Cancer
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Active, closed
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
NCT06187506Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression
Fudan University
Phase 2
20
Shanghai
2023-12-18
Not yet open
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
NCT06152978Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
NCT06177301Nasopharyngeal Carcinoma
Fudan University
Phase 3
266
Shanghai
2023-12-01
Recruiting
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
NCT06158919Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University
Not applicable
58
Shanghai
2023-11-20
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Fudan University
Phase 3
100
Shanghai
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Cohort of Twin Pregnancy and the Offspring
NCT05727085Twin Pregnancy
Fudan University
Observational
1,000
Shanghai
2023-10-15
Active, closed
Acute Health Effects of Low Temperature Exposure
NCT06076629Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
50
Shanghai
2023-10-10
Recruiting
LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
NCT05939063Left-sided Pancreatic Cancer
Fudan University
Not applicable
160
Shanghai
2023-10-01
Not yet open
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
NCT05860907Breast Cancer Stage IV
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
NCT06032845Solid Tumor, Adult
Fudan University
Phase 2
25
Shanghai
2023-09-13
Recruiting
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
NCT06085690CRBSI - Catheter Related Bloodstream Infection, Evidence-based Nursing Practice, Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Associated Bloodstream Infection
Fudan University
Not applicable
8,050
Shanghai
2023-09-04
Not yet open
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
NCT05354674Colorectal Cancer, Liver Metastases
Fudan University
Observational
302
Shanghai
2023-09-01
Recruiting
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
NCT06039631Larynx Cancer, Hypopharyngeal Cancer
Fudan University
Phase 2
82
Shanghai
2023-08-22
Active, closed
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
NCT06020066Brain Metastases, Non-small Cell Lung Cancer
Fudan University
Phase 2
202
Shanghai
2023-08-10
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
NCT05954078High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Phase 3
340
Shanghai
2023-08-01
Recruiting
Novel Therapy Target in Metastatic Prostate Cancer
NCT05577689Prostate Neoplasms
Fudan University
Observational
100
Shanghai
2023-08-01
Active, closed
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
NCT05924256Advanced Salivary Gland Carcinoma
Fudan University
Phase 2
88
Shanghai
2023-07-26
Recruiting
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
NCT05949541Breast Cancer, Advanced Breast Cancer
Fudan University
Phase 2
265
Shanghai
2023-07-26
Recruiting
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
NCT06354231Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney
Fudan University
Phase 2
20
Shanghai
2023-07-20
Active, closed
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
NCT05969899Colorectal Cancer
Fudan University
Phase 2
50
Shanghai
2023-07-10
Not yet open
Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness
NCT05881746Colorectal Carcinoma, Liver Metastases
Fudan University
Not applicable
176
Shanghai
2023-07-01
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
NCT05883852HER2 Positive Early Breast Cancer
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University
Phase 3
1,736
Shanghai
2023-06-01
Recruiting
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093Breast Cancer
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
NCT05861271Breast Cancer Stage I
Fudan University
Phase 2
1,008
Shanghai
2023-06-01
Not yet open
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
NCT05717582Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
Fudan University
Phase 2
47
Shanghai
2023-05-01
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060Triple-Negative Breast Cancer
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT05963490Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
108
Shanghai
2023-04-25
Recruiting
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT06031246Lung Adenocarcinoma, Lymph Node Metastasis
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
NCT06031181Lung Adenocarcinoma, Frozen Section, Sublobar Resection
Fudan University
Phase 3
390
Shanghai
2023-03-31
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378Triple-Negative Breast Cancer
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Active, closed
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer๏ผˆGALAXY๏ผ‰
NCT05824325Breast Cancer
Fudan University
Phase 1/2
56
Shanghai
2023-03-14
Active, closed
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572Breast Cancer Metastatic
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
NCT05771181Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma
Fudan University
Phase 2
25
Shanghai
2023-03-01
Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
NCT05847855Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
Fudan University
Observational
1,000
Shanghai, Chengdu
2023-02-27
Recruiting
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
NCT05717803Segmentectomy, Lung Adenocarcinoma
Fudan University
Phase 3
307
Shanghai
2023-02-15
Recruiting
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546Breast Cancer Metastatic
Fudan University
Phase 2
200
Shanghai
2023-02-01
Recruiting
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
NCT05975749Gastric Cancer
Fudan University
Phase 2
114
Shanghai
2023-01-01
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
Fudan University
Phase 2
55
Shanghai
2023-01-01
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
NCT05587543Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1
24
Shanghai
2022-12-28
Recruiting
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
NCT05555888Early Low Rectal Cancer
Fudan University
Phase 2
34
Shanghai
2022-12-12
Not yet open
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
NCT05359393Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
Fudan University
Phase 2
52
Shanghai
2022-12-01
Recruiting
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
NCT05628038Recurrent Rectal Cancer
Fudan University
Phase 2
93
Shanghai
2022-11-30
Recruiting
Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial
NCT05326932Acute Ischemic Stroke
Fudan University
Not applicable
336
Shanghai
2022-11-03
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
Fudan University
Phase 2
716
Shanghai
2022-11-01
Active, closed
Acute Health Effects of High Temperature Exposure
NCT05575752Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
30
Shanghai
2022-10-23
Recruiting
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
NCT05668884Biliary Tract Carcinoma
Fudan University
Phase 2
93
Shanghai
2022-10-18
Rows per page Showing 301–400 of 472
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 472 of those studies that match the filters currently applied.

How many clinical trials are recruiting in China?

308 of the 472 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 107 have not yet opened recruitment, 51 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Browse trials by condition

Breast Cancer (48) Colorectal Cancer (19) Pancreatic Cancer (14) Gastric Cancer (11) Rectal Cancer (8) Esophageal Squamous Cell Carcinoma (7) Radiotherapy (7) Breast Cancer Metastatic (7) Neoadjuvant Therapy (6) Thyroid Cancer (6) Ovarian Cancer (6) Gastric (Stomach) Cancer (5) Nasopharyngeal Carcinoma (5) Lung Adenocarcinoma (5) Esophageal Cancer (5)

Browse trials by site location

Shanghai (454) Fuzhou (9) Hangzhou (8) Zhengzhou (7) Yangzhou (5) Nantong (5) Tongling (5) Changsha (4) Chongqing (4) Beijing (4) Guangzhou (4) Shijiazhuang (4) Wuhan (3) Anyang (3) Xiamen (3)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.